MCID: DRG011
MIFTS: 51

Drug Addiction malady

Categories: Genetic diseases

Aliases & Classifications for Drug Addiction

Aliases & Descriptions for Drug Addiction:

Name: Drug Addiction 54 52
Polysubstance Abuse 52 69
Polysubstance Abuse, Susceptibility to 29
Drug Addiction, Susceptibility to 13
Drug Dependence 69

Classifications:



External Ids:

OMIM 54 606581

Summaries for Drug Addiction

MalaCards based summary : Drug Addiction, also known as polysubstance abuse, is related to hepatitis d and autism spectrum disorder. An important gene associated with Drug Addiction is FAAH (Fatty Acid Amide Hydrolase), and among its related pathways/superpathways are Peptide ligand-binding receptors and Beta-Adrenergic Signaling. The drugs Buprenorphine and Cocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and amygdala, and related phenotypes are shRNA abundance <= 50% and behavior/neurological

Description from OMIM: 606581

Related Diseases for Drug Addiction

Diseases related to Drug Addiction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
id Related Disease Score Top Affiliating Genes
1 hepatitis d 29.4 COMT DRD2 DRD4
2 autism spectrum disorder 29.2 COMT DRD4 OPRM1
3 schizophrenia 28.6 COMT DRD1 DRD2 DRD3 DRD4
4 substance dependence 11.1
5 acute contagious conjunctivitis 10.2 DRD2 OPRM1
6 rhinoscleroma 10.2 COMT DRD2
7 peripheral vertigo 10.2 COMT OPRM1
8 encephalopathy 10.1 COMT OPRM1
9 apperceptive agnosia 10.1 COMT DRD2
10 teratoma with malignant transformation 10.1 DRD2 DRD3
11 hepatitis 10.1
12 giant cell reparative granuloma 10.1 COMT FAAH
13 strongyloidiasis 10.1 COMT DRD2
14 urea cycle disorder 10.0 COMT DRD2
15 breast reconstruction 10.0 COMT DRD2
16 basal cell carcinoma 3 10.0 COMT DRD2 OPRM1
17 testicular leydig cell tumor 10.0 COMT FAAH OPRM1
18 transmitted_by 10.0 DRD2 DRD3 OPRM1
19 neuronitis 10.0
20 rectosigmoid junction neoplasm 10.0 DRD2 DRD4
21 18p deletion syndrome 10.0 DRD2 DRD4 OPRM1
22 ischemic neuropathy 10.0 DRD2 DRD3
23 colorectal adenocarcinoma 10.0 COMT DRD2 DRD4
24 carotid stenosis 9.9 COMT DRD2 DRD4
25 sphenoorbital meningioma 9.9 DRD2 DRD3 DRD4
26 intracranial aneurysm 9.9 DRD2 DRD3 DRD4
27 aortic valve disease 2 9.9 COMT DRD2 DRD4
28 hepatitis c 9.9
29 obesity 9.9
30 mucinous adenocarcinoma 9.9 DRD2 DRD3 DRD4
31 substance abuse 9.9
32 microcephaly 13, primary, autosomal recessive 9.9 DRD2 DRD3 DRD4
33 mononeuritis multiplex 9.8
34 subdural empyema 9.8
35 bacterial meningitis 9.8
36 meningitis 9.8
37 suppurative periapical periodontitis 9.8 CREB1 DRD2 DRD3 OPRM1
38 parotid gland cancer 9.8 COMT DRD1 DRD2
39 hypereosinophilic syndrome 9.8 DRD2 DRD3 DRD4 OPRM1
40 brain glioblastoma multiforme 9.8 COMT CREB1 DRD2 DRD3
41 alopecia 9.8 DRD2 DRD3 DRD4 FAAH
42 endocarditis 9.8
43 pathological gambling 9.8
44 cerebritis 9.8
45 cecal benign neoplasm 9.8 COMT DRD2 DRD3 DRD4
46 benign epilepsy with centrotemporal spikes 9.8 COMT CREB1 DRD2 DRD4
47 primary angle-closure glaucoma 9.7 COMT DRD1
48 hypoglycemia 9.7 DRD1 DRD2 DRD3 OPRM1
49 cocaine dependence 9.7
50 viral hepatitis 9.7

Graphical network of the top 20 diseases related to Drug Addiction:



Diseases related to Drug Addiction

Symptoms & Phenotypes for Drug Addiction

Clinical features from OMIM:

606581

GenomeRNAi Phenotypes related to Drug Addiction according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 shRNA abundance <= 50% GR00343-S 9.17 COMT DRD1 DRD2 DRD3 DRD4 FAAH

MGI Mouse Phenotypes related to Drug Addiction:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 COMT CREB1 DRD1 DRD2 DRD3 DRD4
2 homeostasis/metabolism MP:0005376 9.81 OPRM1 COMT CREB1 DRD1 DRD2 DRD3
3 adipose tissue MP:0005375 9.77 DRD1 DRD2 DRD3 GPSM1 OPRM1
4 cardiovascular system MP:0005385 9.73 COMT CREB1 DRD1 DRD2 DRD3 GPSM1
5 muscle MP:0005369 9.35 CREB1 DRD1 DRD2 FAAH GPSM1
6 nervous system MP:0003631 9.28 COMT CREB1 DRD1 DRD2 DRD3 DRD4

Drugs & Therapeutics for Drug Addiction

Drugs for Drug Addiction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 538)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 52485-79-7 40400 644073
2
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2 137-58-6 3676
5
Ondansetron Approved Phase 4,Phase 3,Phase 2,Phase 1 99614-02-5 4595
6
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
7
Hydrocodone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 125-29-1 5284569
8
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2 76-42-6 5284603
9
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 27203-92-5 33741
10
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 249296-44-4 5310966
11
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
12
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 561-27-3 5462328
13
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
14
Trazodone Approved, Investigational Phase 4,Phase 3 19794-93-5 5533
15
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
16
Lamotrigine Approved, Investigational Phase 4,Phase 2,Phase 3 84057-84-1 3878
17
Budesonide Approved Phase 4 51333-22-3 63006 5281004
18
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 465-65-6 5284596
19
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
20
Amphetamine Approved, Illicit Phase 4,Phase 3,Phase 1,Phase 2 300-62-9 5826 3007
21
Bupropion Approved Phase 4,Phase 2,Phase 3,Phase 1 34841-39-9, 34911-55-2 444
22
Methylphenidate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 113-45-1 4158
23
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 16590-41-3 5360515
24
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112111-43-0
25
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 537-46-2 10836
26
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 68693-11-8 4236
27
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
28
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
29
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
30
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 68602 5311068 56032
31
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
32
Valproic Acid Approved, Investigational Phase 4,Phase 3 99-66-1 3121
33
Aripiprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 129722-12-9 60795
34
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
35
Phenobarbital Approved Phase 4 50-06-6 4763
36
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 59729-33-8 2771
37
Azacitidine Approved, Investigational Phase 4 320-67-2 9444
38
Clozapine Approved Phase 4 5786-21-0 2818
39
Dextroamphetamine Approved, Illicit Phase 4,Phase 1,Phase 2,Early Phase 1 51-64-9 5826
40
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
41
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 77337-76-9 71158
42
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
43
Tiagabine Approved Phase 4,Phase 3,Phase 2,Phase 1 115103-54-3 60648
44
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
45
Vortioxetine Approved Phase 4 508233-74-7 9966051
46
Sulpiride Approved Phase 4 15676-16-1 5355
47
Disulfiram Approved Phase 4,Phase 1,Phase 2 97-77-8 3117
48
Lorazepam Approved Phase 4,Phase 3,Phase 1,Phase 2 846-49-1 3958
49
Oxazepam Approved Phase 4 604-75-1 4616
50
Sodium oxybate Approved Phase 4 502-85-2 5360545

Interventional clinical trials:

(show top 50) (show all 1312)
id Name Status NCT ID Phase
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4
2 Duration of Behavioral Counseling Treatment Needed to Optimize Smoking Abstinence Unknown status NCT01038414 Phase 4
3 Pharmacologic MRI in Cocaine Addiction Unknown status NCT01652378 Phase 4
4 Comparison of Tramacet Versus Percocet in Post Surgical Patients Unknown status NCT02361567 Phase 4
5 Varenicline Adjunctive Treatment in Schizophrenia Unknown status NCT00492349 Phase 4
6 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4
7 Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans Unknown status NCT01662297 Phase 4
8 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4
9 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Unknown status NCT01846962 Phase 4
10 Treatment of Hepatitis C in Psychiatric Patients Completed NCT00751426 Phase 4
11 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
12 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4
13 Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation Completed NCT01070680 Phase 4
14 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
15 Dexmedetomidine for Sepsis in ICU Randomized Evaluation Trial Completed NCT01760967 Phase 4
16 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4
17 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4
18 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
19 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4
20 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4
21 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4
22 Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy Completed NCT01980550 Phase 4
23 The Whole Day First Grade Program Completed NCT00257088 Phase 4
24 Varenicline in Drug Treatment Completed NCT01286584 Phase 4
25 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine Completed NCT00314340 Phase 4
26 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4
27 Efficacy of Escitalopram in the Treatment of Internet Addiction Completed NCT00565422 Phase 4
28 Preventing Depression Relapse With Mindfulness-Based Cognitive Therapy Completed NCT00183560 Phase 4
29 Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction Completed NCT02626494 Phase 4
30 Switching Antipsychotics: Abrupt Discontinuation Versus Overlap Completed NCT02640300 Phase 4
31 Distribution of Bupropion and Varenicline to Increase Smoking Cessation Attempts Completed NCT01023659 Phase 4
32 Omega-3 Supplementation to ADHD Medication in Children Completed NCT02204410 Phase 4
33 Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic Completed NCT00381043 Phase 4
34 Effectiveness of Varenicline: Testing Individual Differences Completed NCT01228175 Phase 4
35 STOP Study: Effectiveness of Zyban in a Clinical Population Completed NCT01015170 Phase 4
36 Hepatic Function in Alcoholics Following 5 Days of Acetaminophen Dosing Completed NCT00427206 Phase 4
37 Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia Completed NCT01850953 Phase 4
38 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4
39 Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") Completed NCT00955162 Phase 4
40 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4
41 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
42 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4
43 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4
44 Effect of Behavioral Training on Physiological Responses to Smoking Cues, Affect and Cortisol Completed NCT01362101 Phase 4
45 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4
46 A Stepwise Strategy Utilizing Buprenorphine and Methadone Completed NCT00310934 Phase 4
47 Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction Completed NCT00174850 Phase 4
48 Acamprosate: Genes Associated With Response Completed NCT00662571 Phase 4
49 Smoking Relapse Prevention in Schizophrenia Completed NCT00320697 Phase 4
50 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4

Search NIH Clinical Center for Drug Addiction

Genetic Tests for Drug Addiction

Genetic tests related to Drug Addiction:

id Genetic test Affiliating Genes
1 Polysubstance Abuse, Susceptibility to 29

Anatomical Context for Drug Addiction

MalaCards organs/tissues related to Drug Addiction:

39
Brain, Cortex, Amygdala, Lung, Prefrontal Cortex, Testes, Pituitary

Publications for Drug Addiction

Articles related to Drug Addiction:

(show top 50) (show all 630)
id Title Authors Year
1
The Role of NFkB in Drug Addiction: Beyond Inflammation. ( 28043969 )
2017
2
Insights from Preclinical Choice Models on Treating Drug Addiction. ( 27916279 )
2017
3
Is biological aging accelerated in drug addiction? ( 27774503 )
2017
4
Sepsis and persisting neutropenia in a drug addict. ( 28052478 )
2017
5
Ventral medial prefrontal cortex (vmPFC) as a target of the dorsolateral prefrontal modulation by transcranial direct current stimulation (tDCS) in drug addiction. ( 27138429 )
2016
6
Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction. ( 27562376 )
2016
7
Fischer 344 and Lewis Rat Strains as a Model of Genetic Vulnerability to Drug Addiction. ( 26903787 )
2016
8
Drug addiction: An affective-cognitive disorder in need of a cure. ( 27095547 )
2016
9
Pain Control in the Presence of Drug Addiction. ( 27068665 )
2016
10
The potential biomarkers of drug addiction: proteomic and metabolomics challenges. ( 27328859 )
2016
11
RELATIONSHIP OF ASSESS SELF-ESTEEM AND LOCUS OF CONTROL WITH QUALITY OF LIFE DURING TREATMENT STAGES IN PATIENTS REFERRING TO DRUG ADDICTION REHABILITATION CENTERS. ( 27698598 )
2016
12
Caenorhabditis elegans as a Model to Study the Molecular and Genetic Mechanisms of Drug Addiction. ( 26810004 )
2016
13
Drug addiction stigma in relation to methadone maintenance treatment by different service delivery models in Vietnam. ( 26956741 )
2016
14
CYP gene family variants as potential protective factors in drug addiction in Han Chinese. ( 27257124 )
2016
15
Attachment Theory and Maternal Drug Addiction: The Contribution to Parenting Interventions. ( 27625612 )
2016
16
Drug Addiction: A Global Challenge. ( 27377484 )
2016
17
Is there any relationship between drug addiction and the development of a signet ring cell carcinoma of the stomach? ( 26817508 )
2016
18
Sex differences in impulsive and compulsive behaviors: a focus on drug addiction. ( 26935237 )
2016
19
Similarity and Difference in Drug Addiction Process Between Heroin- and Methamphetamine-Dependent Users. ( 28001458 )
2016
20
Editorial: Exploring Gender and Sex Differences in Behavioral Dyscontrol: From Drug Addiction to Impulse Control Disorders. ( 26941657 )
2016
21
Pre-incarceration police harassment, drug addiction and HIV risk behaviours among prisoners in Kyrgyzstan and Azerbaijan: results from a nationally representative cross-sectional study. ( 27435715 )
2016
22
Maximizing Health or Sufficient Capability in Economic Evaluation? A Methodological Experiment of Treatment for Drug Addiction. ( 27856827 )
2016
23
Glutamate and Brain Glutaminases in Drug Addiction. ( 28012058 )
2016
24
A significant association between BDNF promoter methylation and the risk of drug addiction. ( 26976342 )
2016
25
Attention deficit-hyperactivity disorder in patients in rehabilitation of drug addiction. ( 27991991 )
2016
26
Mothering from the Inside Out: A mentalization-based therapy for mothers in treatment for drug addiction. ( 27840685 )
2016
27
Attention deficit hyperactivity disorder and drug addiction rehabilitation patients. ( 27991999 )
2016
28
Targeting the ecology within: The role of the gut-brain axis and human microbiota in drug addiction. ( 27372861 )
2016
29
Moving Clinical Deliberations on Administrative Discharge in Drug Addiction Treatment Beyond Moral Rhetoric to Empirical Ethics. ( 27045311 )
2016
30
Romantic Love vs. Drug Addiction May Inspire a New Treatment for Addiction. ( 27713720 )
2016
31
Understanding the Subjective Experience of Medication Adherence for Older Urban African Americans With Type 2 Diabetes and a History of Illicit Drug Addiction. ( 26965082 )
2016
32
Dopamine D4 receptor stimulation prevents nigrostriatal dopamine pathway activation by morphine: relevance for drug addiction. ( 27212105 )
2016
33
S-Glutathionylation and Redox Protein Signaling in Drug Addiction. ( 26809999 )
2016
34
The Therapeutic Utility of Employment in Treating Drug Addiction: Science to Application. ( 27777966 )
2016
35
"Not just eliminating the mosquito but draining the swamp": A critical geopolitics of Turkish Monitoring Center for Drugs and Drug Addiction and Turkey's approach to illicit drugs. ( 27267659 )
2016
36
Construct Validity of Symptom Checklist-90-Revised (SCL-90-R) and General Health Questionnaire-28 (GHQ-28) in Patients with Drug Addiction and Diabetes, and Normal Population. ( 27252914 )
2016
37
A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction: An Editorial from a Legal Perspective. ( 27055610 )
2016
38
Self-deception as a mechanism for the maintenance of drug addiction. ( 26820418 )
2016
39
Autism Spectrum Disorders and Drug Addiction: Common Pathways, Common Molecules, Distinct Disorders? ( 26903789 )
2016
40
Heantos-4, a natural plant extract used in the treatment of drug addiction, modulates T-type calcium channels and thalamocortical burst-firing. ( 27919294 )
2016
41
Acupuncture therapy for drug addiction. ( 27053944 )
2016
42
Psychiatric comorbidity in a sample of cocaine-dependent outpatients seen in the Community of Madrid drug addiction care network. ( 26990385 )
2016
43
Lived Time Disturbances of Drug Addiction Therapy Newcomers. A Qualitative, Field Phenomenology Case Study at Monar-Markot Center in Poland. ( 27942253 )
2016
44
Genetic polymorphisms in ALDH2 are associated with drug addiction in a Chinese Han population. ( 28052001 )
2016
45
The good and bad news about glutamate in drug addiction. ( 27353027 )
2016
46
Portraying mental illness and drug addiction as treatable health conditions: effects of a randomized experiment on stigma and discrimination. ( 25528557 )
2015
47
The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. ( 25823631 )
2015
48
The rewarding properties of methamphetamine in an invertebrate model of drug addiction. ( 26477734 )
2015
49
Promoter Methylation and BDNF and DAT1 Gene Expression Profiles in Patients with Drug Addiction. ( 26160290 )
2015
50
Landmark Legislation to Expand Treatment for Heroin and Prescription Drug Addiction. ( 26340575 )
2015

Variations for Drug Addiction

ClinVar genetic disease variations for Drug Addiction:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 FAAH NM_001441.2(FAAH): c.385C> A (p.Pro129Thr) single nucleotide variant risk factor rs324420 GRCh37 Chromosome 1, 46870761: 46870761

Expression for Drug Addiction

Search GEO for disease gene expression data for Drug Addiction.

Pathways for Drug Addiction

Pathways related to Drug Addiction according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 DRD1 DRD2 DRD3 DRD4 GPSM1 OPRM1
2
Show member pathways
12.48 DRD1 DRD2 DRD3 DRD4
3
Show member pathways
12.21 DRD1 FAAH OPRM1
4 12.2 COMT CREB1 OPRM1
5
Show member pathways
11.97 CREB1 DRD1 DRD2
6
Show member pathways
11.94 CREB1 DRD1 DRD2 DRD4
7 11.91 CREB1 DRD1 DRD2 DRD3 DRD4
8
Show member pathways
11.77 COMT CREB1 DRD1 DRD2 DRD3 DRD4
9
Show member pathways
11.69 CREB1 DRD1 DRD2 GPSM1
11
Show member pathways
11.62 DRD2 DRD3 DRD4
12
Show member pathways
11.62 DRD1 DRD2 DRD3 DRD4
13 10.94 DRD1 DRD2 DRD3

GO Terms for Drug Addiction

Cellular components related to Drug Addiction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.55 DRD1 DRD2 DRD3 DRD4 OPRM1
2 endocytic vesicle GO:0030139 9.37 DRD2 DRD3
3 ciliary membrane GO:0060170 9.32 DRD1 DRD2
4 postsynapse GO:0098794 9.26 DRD4 OPRM1
5 non-motile cilium GO:0097730 8.96 DRD1 DRD2
6 axon GO:0030424 8.92 COMT CREB1 DRD2 OPRM1

Biological processes related to Drug Addiction according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.97 COMT CREB1 DRD1 DRD2 DRD3
2 locomotory behavior GO:0007626 9.85 DRD1 DRD2 DRD3 OPRM1
3 response to ethanol GO:0045471 9.84 DRD2 DRD3 OPRM1
4 learning GO:0007612 9.79 COMT DRD1 DRD3
5 response to morphine GO:0043278 9.76 DRD2 DRD3 OPRM1
6 visual learning GO:0008542 9.76 CREB1 DRD1 DRD2 DRD3
7 arachidonic acid secretion GO:0050482 9.75 DRD2 DRD3 DRD4
8 synaptic transmission, dopaminergic GO:0001963 9.73 DRD1 DRD2 DRD3
9 response to cocaine GO:0042220 9.73 DRD1 DRD2 DRD3 OPRM1
10 circadian regulation of gene expression GO:0032922 9.72 DRD2 DRD3
11 social behavior GO:0035176 9.72 DRD3 DRD4
12 regulation of circadian rhythm GO:0042752 9.71 CREB1 DRD4
13 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.71 DRD1 OPRM1
14 feeding behavior GO:0007631 9.71 DRD1 DRD2
15 response to nicotine GO:0035094 9.71 CREB1 DRD2
16 negative regulation of protein kinase B signaling GO:0051898 9.71 DRD2 DRD3
17 behavioral response to ethanol GO:0048149 9.71 DRD2 DRD4 OPRM1
18 positive regulation of cytokinesis GO:0032467 9.7 DRD2 DRD3
19 positive regulation of multicellular organism growth GO:0040018 9.7 CREB1 DRD2
20 adult walking behavior GO:0007628 9.7 DRD1 DRD2
21 negative regulation of blood pressure GO:0045776 9.7 DRD2 DRD3
22 prepulse inhibition GO:0060134 9.7 DRD1 DRD2 DRD3
23 associative learning GO:0008306 9.69 DRD1 DRD2
24 behavioral fear response GO:0001662 9.69 DRD1 DRD4
25 regulation of sensory perception of pain GO:0051930 9.69 COMT OPRM1
26 negative regulation of protein secretion GO:0050709 9.69 DRD2 DRD3 DRD4
27 regulation of dopamine secretion GO:0014059 9.68 DRD2 DRD3
28 temperature homeostasis GO:0001659 9.68 DRD1 DRD2
29 negative regulation of cAMP biosynthetic process GO:0030818 9.67 DRD4 OPRM1
30 positive regulation of long-term synaptic potentiation GO:1900273 9.67 CREB1 DRD2
31 grooming behavior GO:0007625 9.67 DRD1 DRD2
32 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.67 DRD2 DRD3 DRD4
33 negative regulation of adenylate cyclase activity GO:0007194 9.67 DRD2 DRD3 DRD4 OPRM1
34 positive regulation of renal sodium excretion GO:0035815 9.66 DRD2 DRD3
35 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.65 DRD1 DRD2
36 negative regulation of voltage-gated calcium channel activity GO:1901386 9.65 DRD2 DRD4
37 G-protein coupled receptor internalization GO:0002031 9.65 DRD2 DRD3
38 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.65 DRD1 DRD3 OPRM1
39 striatum development GO:0021756 9.64 DRD1 DRD2
40 peristalsis GO:0030432 9.64 DRD1 DRD2
41 regulation of dopamine metabolic process GO:0042053 9.63 DRD1 DRD4
42 regulation of cAMP metabolic process GO:0030814 9.63 DRD2 DRD3
43 cerebral cortex GABAergic interneuron migration GO:0021853 9.62 DRD1 DRD2
44 response to amphetamine GO:0001975 9.62 DRD1 DRD2 DRD3 DRD4
45 negative regulation of dopamine receptor signaling pathway GO:0060160 9.61 DRD2 DRD3
46 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.61 DRD2 DRD4
47 acid secretion GO:0046717 9.6 DRD2 DRD3
48 regulation of locomotion involved in locomotory behavior GO:0090325 9.59 DRD2 DRD3
49 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.58 DRD1 DRD2 DRD3
50 behavioral response to cocaine GO:0048148 9.46 DRD1 DRD2 DRD3 DRD4

Molecular functions related to Drug Addiction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.77 DRD1 DRD2 DRD3 DRD4 OPRM1
2 signal transducer activity GO:0004871 9.65 DRD1 DRD2 DRD3 DRD4 OPRM1
3 drug binding GO:0008144 9.5 DRD2 DRD3 DRD4
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD2 DRD3 DRD4
5 dopamine binding GO:0035240 9.26 DRD1 DRD2 DRD3 DRD4
6 dopamine neurotransmitter receptor activity GO:0004952 8.92 DRD1 DRD2 DRD3 DRD4

Sources for Drug Addiction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....